Schizophrenia and osteoporosis

International Clinical Psychopharmacology

Volumn 19, Issue 1, 2004, Pages 31-35

  Lean, Mike ^a   De Smedt, Goedele ^b,c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Virco BVBA   (Belgium)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Antipsychotic; Osteoporosis; Prolactin; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SULPIRIDE;

AMENORRHEA; ARTICLE; DRUG EFFECT; HIGH RISK POPULATION; HUMAN; HYPERPROLACTINEMIA; LIFESTYLE; MEDICAL CARE; MENTAL PATIENT; OSTEOPOROSIS; PATIENT MONITORING; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BONE AND BONES; HUMANS; HYPERPROLACTINEMIA; OSTEOPOROSIS; PROLACTIN; RISK FACTORS; SCHIZOPHRENIA;

EID: 1642534547     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200401000-00006     Document Type: Article

References (28)

1. Abraham G, Friedman RH, Verghese C, de Leon J (1995). Osteoporosis and schizophrenia: can we limit known risk factors? Biol Psychiatry 38:131-132.
2. Alexiadis M, Whitehorn D, Woodley H, Kopala L (2002). Prolactin elevation with quetiapine. Am J Psychiatry 159:1608-1609.
3. Ataya K, Mercado A, Kartaginer J, Abbasi A, Moghissi KS (1988). Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 50:876-881.
4. Bilici M, Cakirbay H, Guler M, Tosun M, Ulgen M, Tan U (2002). Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 112:817-828.
5. Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, et al. (1999). Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 156:294-298.
6. Chou JC, Douyon R, Czobor P, Volavka J, Cooper TB (1998). Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Res 81:51-55.
7. Cohen AJ, Roe FJ (2000). Review of risk factors for osteoporosis with particular reference to a possible aetiological role of dietary salt. Food Chem Toxicol 38:237-253.
8. De Smedt G, Binder C, Findling R, Kusumakar V (2002). Prolactin serum levels after long-term risperidone treatment [Abstract]. Eur Neuropsychopharmacol 12 (suppl 3):S301.
9. Dickson RA, Glazer WM (1999). Neuroleptic-induced hyperprolactinemia. Schizophr Res 35 (suppl):S75-S86.
10. Francis RM (1999). The effects of testosterone on osteoporosis in men. Clin Endocrinol (Oxf) 50:411-414.
11. Gennari C, Martini G, Nuti R (1998). Secondary osteoporosis. Aging (Milano) 10:214-224.
12. Halbreich U, Palter S (1996). Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 22:447-454.
13. Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, et al. (1995). Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 57:485-491.
14. Kartaginer J, Ataya K, Mercado A, Abbasi A (1990). Osteoporosis associated with neuroleptic treatment. A case report. J Reprod Med 35:198-202.
15. Keely E, Reiss JP, Drinkwater DT, Faiman C (1997). Bone mineral density, sex hormones and longterm use of neuroleptic agents in men. Endocrin Pract 3:209-213.
16. Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, Dickson RA (2002). Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 63:408-413.
17. Kleinberg DL, Davis JM, De Coster R, van Baelen B, Brecher M (1999). Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19:57-61.
18. Malik P (2001). Dissertation for the degree of Doctor in General Medicine. Medical Faculty of the Leopold-Franzens University, Innsbruck, Austria.
19. Markianos M, Hatzimanolis J, Lykouras L (2001). Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci 251:141-146.
20. Masiukiewicz US, Insogna KL (1998). The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis. Aging (Milano) 10:232-239.
21. Meaney AM, O'Keane V (2002). Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci 71:979-992.
22. Nordin BE, Need AG, Steurer T, Morris HA, Chatterton BE, Horowitz M (1998). Nutrition, osteoporosis, and aging. Ann NY Acad Sci 854:336-351.
23. Nordstrom AL, Farde L (1998). Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 18:305-310.
24. Schlechte J, Walkner L, Kathol M (1992). A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Enocinol Metab 75:698-702.
25. Spitzer M, Sajjad R, Benjamin F (1998). Pattern of development of hyperprolactinemia after initiation of haloperidol therapy. Obstet Gynecol 91:693-695.
26. Turrone P, Kapur S, Seeman MV, Flint AJ (2002). Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159:133-135.
27. Wieck A, Haddad P (2002). Hyperprolactinaemia caused by antipsychotic drugs. BMJ 324:250-252.
28. Zhang XY, Zhou DF, Yuan CL, Zhang PY, Wu GY, Shen YC (2002). Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Psychiatry Res 109:297-302.